Towards improving clinical management of Middle East respiratory syndrome coronavirus infection

The Lancet Infectious Diseases

Volumn 14, Issue 7, 2014, Pages 544-546

  Hayden, Frederick G ^a   Farrar, Jeremy ^b   Peiris, J S Malik ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID; NEUTRALIZING ANTIBODY; RIBAVIRIN;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CLINICAL RESEARCH; CONTROLLED CLINICAL TRIAL (TOPIC); CORONAVIRUS; CORONAVIRUS INFECTION; DISEASE ASSOCIATION; EPIDEMIC; HEREDITY; HUMAN; MERS CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; NOTE; PRIORITY JOURNAL; SAUDI ARABIA; SEASONAL VARIATION; SEROPREVALENCE; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT DURATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION; DISEASE SURVEILLANCE; ENVIRONMENTAL EXPOSURE; KIDNEY FAILURE; LUNG INJURY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; PATHOGENESIS; RESPIRATORY FAILURE; VIRUS DETECTION;

CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; MIDDLE EAST; RESPIRATORY TRACT INFECTIONS;

EID: 84904707048     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70793-5     Document Type: Note

References (15)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
2. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
3. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416.
4. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. Lancet 2013, 381:2265-2272.
5. Cauchemez S, Fraser C, Van Kerkhove MD, et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 2014, 14:50-56.
6. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013, 13:745-751.
7. Hui DS, Chan PK Severe acute respiratory syndrome and coronavirus. Infect Dis Clin North Am 2010, 24:619-638.
8. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013, 67:606-616.
9. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
10. Public Health England ISARIC Clinical decision making tool for treatment of MERS-CoV v.1.1, July 29, 2013 (accessed May 9, 2014). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416.
11. WHO-ISARIC joint MERS-CoV Outbreak Readiness Workshop: Clinical management and potential use of convalescent plasma WHO, (accessed May 9, 2014). http://www.who.int/csr/disease/coronavirus_infections/MERS_outbreak_readiness_workshop.pdf?ua=1.
12. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014, 6:234ra59.
13. Houdebine L-M Production of human polyclonal antibodies by transgenic animals. Adv Biosci Biotechnol 2011, 2:138-141.
14. Tillib SV, Ivanova TI, Vasilev LA, et al. Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Res 2013, 97:245-254.
15. Hien TT, Ruiz-Palacios GM, Hayden FG, Farrar J Patient-oriented pandemic influenza research. Lancet 2009, 373:2085-2086.